Reviewing AVAX Technologies (OTCMKTS:AVXT) & Anixa Biosciences (NASDAQ:ANIX)

AVAX Technologies (OTCMKTS:AVXT) and Anixa Biosciences (NASDAQ:ANIX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares AVAX Technologies and Anixa Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AVAX Technologies	N/A	N/A	N/A
Anixa Biosciences	N/A	-70.95%	-62.53%

Valuation and Earnings

This table compares AVAX Technologies and Anixa Biosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AVAX Technologies	N/A	N/A	N/A	N/A	N/A
Anixa Biosciences	$210,000.00	429.50	-$10.93 million	($0.33)	-8.15

AVAX Technologies has higher earnings, but lower revenue than Anixa Biosciences.

Institutional & Insider Ownership

29.1% of Anixa Biosciences shares are held by institutional investors. 6.0% of AVAX Technologies shares are held by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for AVAX Technologies and Anixa Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AVAX Technologies	0	0	0	0	0.00
Anixa Biosciences	1	1	2	0	2.25

Anixa Biosciences has a consensus price target of $8.50, suggesting a potential upside of 215.99%. Given Anixa Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Anixa Biosciences is more favorable than AVAX Technologies.

Summary

Anixa Biosciences beats AVAX Technologies on 6 of the 8 factors compared between the two stocks.

About AVAX Technologies

AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company’s product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

About Anixa Biosciences

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.